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Massive research efforts are now underway to develop a cure for
HIV infection, allowing patients to discontinue lifelong combina-
tion antiretroviral therapy (ART). New latency-reversing agents
(LRAs) may be able to purge the persistent reservoir of latent virus
in resting memory CD4+ T cells, but the degree of reservoir reduc-
tion needed for cure remains unknown. Here we use a stochastic
model of infection dynamics to estimate the efficacy of LRA
needed to prevent viral rebound after ART interruption. We in-
corporate clinical data to estimate population-level parameter dis-
tributions and outcomes. Our findings suggest that ∼2,000-fold
reductions are required to permit a majority of patients to inter-
rupt ART for 1 y without rebound and that rebound may occur
suddenly after multiple years. Greater than 10,000-fold reductions
may be required to prevent rebound altogether. Our results pre-
dict large variation in rebound times following LRA therapy, which
will complicate clinical management. This model provides bench-
marks for moving LRAs from the laboratory to the clinic and can
aid in the design and interpretation of clinical trials. These results
also apply to other interventions to reduce the latent reservoir
and can explain the observed return of viremia after months of
apparent cure in recent bone marrow transplant recipients and
an immediately-treated neonate.
HIV latent reservoir | HIV cure | viral dynamics
The latent reservoir (LR) for HIV-1 is a population of long-lived resting memory CD4+ T cells with integrated HIV-1
DNA (1). After establishment during acute infection (2), it
increases to 105 to 107 cells and then remains stable. As only
replicating virus is targeted by antiretroviral therapy (ART), la-
tently infected cells persist even after years of effective treatment
(3, 4). Cellular activation leads to virus production and, if
treatment is interrupted, viremia rebounds within weeks (5).
Several molecular mechanisms maintain latency, including epi-
genetic modifications, transcriptional interference from host
genes, and the absence of activated transcription factors (6–9).
Major efforts are underway to identify pharmacologic agents
that reverse latency by triggering the expression of HIV-1 genes
in latently infected cells, with the hope that cell death from viral
cytopathic effects or cytolytic immune responses follows, re-
ducing the size of the LR (10, 11). Collectively called latency-
reversing agents (LRAs), these drugs include histone deacetylase
inhibitors (12–14), PKC activators (15–18), and the bromodo-
main inhibitor JQ1 (19–21). Although LRAs are the subject of
intense research, it is unclear how much the LR must be reduced
to enable patients to safely discontinue ART.
The feasibility of reservoir reduction as a method of HIV-1 cure
is supported by case studies of stem cell transplantation (22, 23)
and, more recently, early treatment initiation (24, 25), which have
allowed patients to interrupt treatment for months or years
without viral rebound. The dramatic reductions in reservoir size
accompanying these strategies stands in stark contrast to the
actions of current LRAs, which induce only a fraction of latent
virus in vitro (26, 27) and have not produced a measurable de-
crease in LR size in vivo (12, 13, 28). It is unclear how patient
outcomes depend on reservoir reduction between these extremes,
nor even whether a reduction that falls short of those achieved
with stem cell transplantation will bring any clinical benefit. LRA
research needs to address the question: How low must we go?
In the absence of clinical data, mechanistic mathematical
models can serve as a framework to predict results of novel
interventions and plan clinical trials. When results do become
available, the models can be tested and refined. Mathematical
models have a long tradition of informing HIV-1 research and
have been particularly useful in understanding HIV-1 treatment.
Previous models have explained the multiphasic decay of viremia
during ART (29), the initial seeding of the LR during acute in-
fection (30), the limited inflow to the LR during treatment (31),
the dynamics of viral blips (32), and the contributions of the LR
to drug resistance (33). No model has yet been offered to de-
scribe the effect of LRAs. Here we present a novel modeling
framework to predict the degree of reservoir reduction needed
to prevent viral rebound following ART interruption. The model
can be used to estimate the probability that cure is achieved, or,
barring that outcome, to estimate the length of time following
treatment interruption before viral rebound occurs (Fig. 1A).
Results
Determination of Key Viral Dynamic Parameters Governing Patient
Outcomes. We use a stochastic model of HIV-1 reservoir dy-
namics and rebound that, in its simplest form, tracks two cell
types: productively infected activated CD4+ T cells and latently
infected resting CD4+ T cells (Fig. 1B). A latently infected cell
can either activate or die, each with a particular rate constant.
An actively infected cell can produce virions, resulting in the
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active infection of some number of other cells, or it can die from
other causes without producing virions that infect other cells. In
the latter case, cytotoxic T lymphocyte (CTL) killing, errors in
viral reverse transcription, or other problems upstream of virion
production may prevent further infection. The model only tracks
the initial stages of viral rebound, when target cells are not yet
limited. A full description of the model is provided in Materials
and Methods and SI Materials and Methods.
The initial conditions for the dynamic model depend on the
number of latently infected cells left after LRA therapy. LRA
efficacy is defined by the fraction q of the LR that remains fol-
lowing treatment. The model tracks each latent and active cell to
determine whether viral rebound occurs, and if so, how long it
takes. Importantly, no single activated cell is guaranteed to
reestablish the infection, as it may die before infecting other
cells. Even if it does infect others, those cells likewise may die
before completing further infection. This possibility is a general
property of stochastic models, and the specific value for the es-
tablishment probability depends on the rates at which infection
and death events occur. Our goal is to calculate the probability
that at least one of the infected cells remaining after therapy
escapes extinction and causes viral rebound, and if so, how long
it takes. If all cells die, then rebound never occurs and a cure is
achieved. As the model only describes events after completion of
LRA therapy, our results are independent of the therapy pro-
tocol or mechanism of action.
Using both stochastic simulations and theoretical analysis of
this model, we find that the probability and timing of rebound
relies on four key parameters: the decay rate of the LR in the
absence of viral replication (δ), the rate at which the LR pro-
duces actively infected cells (A), the probability that any one
activated cell will produce a rebounding infection before its
lineage dies (PEst), and the net growth rate of the infection once
restarted (r). Estimates of these four parameters are provided in
Table 1 and Fig. S1. After therapy, the rate at which the LR
produces actively infected cells is reduced to qA. The probability
that an individual successfully clears the infection is
PClrðqÞ≈ e
−qAPEst
δ : [1]
The expression qAPEst/δ approximates the expected number of
fated-to-establish cells that will ever exit from the LR, explaining
the Poisson form of this expression. In SI Materials and Methods,
we provide the full derivation, as well as a formula—[S8]—for
the probability that rebound occurs a given number of days fol-
lowing treatment interruption (a function of δ, A, PEst, r, and
efficacy q). Of note, the initial size of the reservoir itself is not
included among these parameters: although it factors into both A
(the product of the pre-LRA reservoir size and the per-cell ac-
tivation rate), and q (the ratio of post-LRA to pre-LRA reservoir
size), it does not independently influence outcomes. Both of
these formulas provide an excellent match to the explicit simu-
lation of the model (Fig. 2). The key assumption required for the
analysis is that r greatly exceeds δ; because viral doubling times
during rebound are measured on the order of a few days,
whereas LR decay is measured on the order of many months
or years, this assumption is expected to hold. Likelihood-based
inference can therefore proceed by efficient computation of re-
bound probabilities (using [S8]), rather than by time-consuming
stochastic simulation.
Outcomes depend only on the four parameters above even in
more complex models of viral dynamics, including other features
of T-cell biology and the HIV lifecycle (SI Materials and Meth-
ods). Alternate models studied include explicit tracking of free
virus with varying burst sizes, an eclipse phase during which an
infected cell produces no virus, proliferation of cells upon reac-
tivation, maintenance of the LR by homeostatic proliferation, and
either a constant or Poisson-distributed number of infected
cells produced by each cell (Figs. S2–S7). If proliferation of
latently infected cells is subject to high variability, e.g., by bursts
of proliferation, then rebound time and cure probability increase
slightly beyond the predictions of the basic model (Figs. S6 and S7).
No other modification to the model altered outcomes. Outcomes
of LRA therapy therefore are likely to be insensitive to details of
the viral lifecycle; accordingly, few parameters must be estimated
to predict outcomes.
Predicted Prospects for Eradicating Infection or Delaying Time to
Rebound. Using best estimates of parameters derived from pre-
viously reported data (Table 1), we can explore the likely out-
comes of interventions that reduce the LR. The best outcome of
LRA therapy, short of complete and immediate eradication, is
that so few latently infected cells survive that none reactivate and
start a resurgent infection during the patient’s lifespan. In this
case, LRA has essentially cleared the infection and cure is
achieved. We simulated the model to predict the relationship
between LRA efficacy and clearance (Fig. 2A). We find that
the LR must be reduced 10,000-fold before half of patients
are predicted to clear the infection.
If LRA therapy fails to clear the infection, the next-best out-
come is extension of the time until rebound, defined as plasma
HIV-1 RNA ≥ 200 copies per mL. We computed the relationship
between LRA efficacy and median time until rebound among
patients who do not clear the infection (Fig. 2B). Roughly a 2,000-
fold reduction in LR size is needed for median rebound times of
1 y. Only modest (about 2-fold) increases in median rebound time
are predicted for up to 100-fold reductions in LR size. In this
range, the rebound time is independent of latent cell lifespan
(decay rate δ) and is driven mainly by the reactivation rate (A) and
the infection growth rate (r). The curve inflects upward (on a log
scale) at ∼100-fold reduction and eventually reaches a ceiling as
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Fig. 1. Schematic of LRA treatment and stochastic model of rebound fol-
lowing interruption of ART. (A) Proposed treatment protocol, illustrating
possible viral load and size of LR before and after LRA therapy. When ART is
started, viral load decreases rapidly and may fall below the limit of de-
tection. The LR is established early in infection (not shown) and decays very
slowly over time. When LRA is administered, the LR declines. After discon-
tinuation of ART, the infection may be cleared, or viremia may eventually
rebound. (B) LRA efficacy is defined by the parameter q, the fraction of the
LR remaining after therapy, which determines the initial conditions of the
model. The stochastic model of viral dynamics following interruption of ART
and LRA tracks both latently infected resting CD4+ T cells (rectangles) and
productively infected CD4+ T cells (ovals). Each arrow represents an event
that occurs in the model. Alternate models considering homeostatic pro-
liferation and turnover of the LR are discussed in SI Materials and Methods.
Viral rebound occurs if at least one remaining cell survives long enough to
activate and produce a chain of infection events leading to detectable in-
fection (plasma HIV-1 RNA >200 copies per mL).
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clearance of the infection becomes the dominant outcome. The
upward inflection results from a change in the forces governing viral
dynamics. If the reservoir is large (little reduction), then cells
activate frequently, and the dominant component of rebound
time is the time that it takes for virus from the many available
activated cells to grow exponentially to rebound levels; the sys-
tem is in a growth-limited regime. If the reservoir is small (large
reduction), the dominant component is instead the expected
waiting time until activation of the first cell fated to establish
a rebounding lineage; the system is in an activation-limited regime.
Because waiting time is roughly exponentially distributed, times
to rebound in this regime can vary widely among patients on
the same therapy, even with identical values of the underlying
parameters.
Survival curves, plotting the fraction of simulated patients
maintaining virologic suppression over time, demonstrate the
extreme interpatient variability and long follow-up times required
for LRA therapy (Fig. 2C). For less than 100-fold reductions
in LR size, simulated patients uniformly rebound within a few
months because rebound dynamics are not in the activation-
limited regime. If therapy decreases LR size 1,000-fold, then
∼55% of patients are predicted to delay rebound for at least
6 mo. However, of these patients, 47% suffer rebound in the
following 6 mo. Higher reservoir reductions lead to clearance in
many patients. In others, rebound may still occur after years of
apparent cure, posing a challenge for patient management.
Earlier work suggested a shorter reservoir half-life of 6 mo
(35), indicating that dramatic decreases in LR size would occur
after 5 y or more of suppressive ART even in the absence of
LRA therapy. We consider the prospects for HIV eradication
or long treatment interruptions with this faster decay rate. In
this optimistic scenario, only 1,500-fold reductions are needed
for half of patients to clear the LR, and rebound becomes highly
unlikely after a few years. Alternatively, in a worst-case scenario
where latent cell death is perfectly balanced by homeostatic
proliferation such that the reservoir does not decay at all (δ = 0),
much higher efficacies are needed to achieve beneficial patient
outcomes (Fig. 3).
Setting Treatment Goals with Uncertainty Considerations. We con-
ducted a full uncertainty analysis of the model, by simultaneously
varying all parameters over their entire ranges (Table 1 and Fig.
S1). For each simulated patient, values for the three parameters
δ, A, and r were sampled independently from their respective
distributions, whereas PEst was sampled from a conditional dis-
tribution that depends on r (Materials and Methods). Results for
this simulated cohort are similar to those for the point estimates,
with greater interpatient variation in outcomes (Fig. 3A). This
variation makes the survival curves less steep: Cure is slightly
more likely at low efficacy, but slightly less likely at high efficacy.
As expected from Eq. 1, cure is more likely for patients with
lower A or PEst values and higher δ values. If therapy provides
only 10 to 100-fold LR reductions, a subset of patients may delay
rebound for several months.
Using these cohort-level predictions, we can set efficacy goals
for the reservoir reduction needed to achieve a particular like-
lihood of a desired patient outcome. Fig. 4 provides target LRA
efficacies for which 50% of patients are predicted to remain
rebound-free for a specified interruption time. Reductions of
under 10-fold afford patients only a few weeks to a month off
treatment without rebound. For 1-y interruptions, a 1,000–3,000-
fold reduction is needed. To achieve the goal of eradication
(cure) a 4-log reduction is required. This value increases to 4.8
logs to cure 75% of patients, and to 5.8 logs for 95% of patients.
Model Applications and Comparison with Data. The current ability
to test the model against clinical data is limited both by the dy-
namic range of assays measuring LR size and by the low efficacy
of investigational LRA treatments. However, we can compare our
predictions to results observed for non–LRA-based interventions
that lead to smaller LR size and prolonged treatment inter-
ruptions (Fig. 4). A 2010 study of early ART initiators who
eventually underwent treatment interruption found a single pa-
tient with LR size ∼1,500-fold lower than a typical patient (0.0064
infectious units per million resting CD4+ T cells versus an average
of one per million) in whom rebound was delayed until 50 d off
treatment (36). The well-known “Berlin patient” (22) has re-
mained off treatment following a stem cell transplant since 2008,
and a comprehensive analysis of his viral reservoirs found HIV
DNA levels at least 7,500-fold lower than typical patients in the
most sensitive assay (37). The two recently reported “Boston
patients” also interrupted treatment, following transplants causing
at least a 3 to 4 log decrease in viral reservoirs (23); they have since
both rebounded, at ∼3 and 8 mo postinterruption. In the case of
the “Mississippi baby”, infection was discovered and treated within
30 h of birth, and ART continued until interruption at around
18 mo. Virus remained undetectable for 27 mo, when viral rebound
occurred, assuming the accuracy of widely reported claims (e.g.,
ref. 38). At the time of treatment cessation, the LR size was likely
at least 300-fold lower than that of a typical adult [based on less
than 0.017 infectious units per million resting CD4+ T cells at age
30 mo (39), and scaled on a weight basis relative to adults]. These
few available cases demonstrate that our model is not inconsistent
Table 1. Estimated values for the key parameters of the stochastic viral dynamics model
Parameter Symbol Estimation method Ref(s). Best estimate Distribution*
LR decay rate δ Long-term ART, δ = ln(2)/τ1/2 (6, 7) 5.2 × 10
−4 d−1 δ≈Nð5:2,1:6Þ× 10−4 d−1
LR exit rate A Viral rebound after ART interruption (8, 69) 57 cells per day log10ðAÞ≈Nð1:76,1:0Þ
Growth rate r 0.4 d−1 log10ðrÞ≈Nð−0:40,0:19Þ
Establishment probability PEst Population genetic modeling (71, 72) 0.069 Composite distribution
(Materials and Methods)
*Notation X ≈Nðμ,σÞ means that X is a random variable drawn from a normal distribution with mean μ and SD σ.
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Fig. 2. Clearance probabilities and rebound times following LRA therapy
predicted from the model using point estimates for the parameters (Table 1).
LRA log-efficacy is the number of orders of magnitude by which the LR size is
reduced following LRA therapy, −log10(q). (A) Probability that the LR is
cleared by LRA. Clearance occurs if all cells in the LR die before a reactivating
lineage leads to viral rebound. (B) Median viral rebound times (logarithmic
scale) among patients who do not clear the infection. (C) Survival curves
(Kaplan–Meier plots) show the percentage of patients who have not yet
experienced viral rebound, plotted as a function of the time (logarithmic
scale) after treatment interruption. Solid lines represent simulations, and
circles represent approximations from the branching process calculation. All
simulations included 104 to 105 patients.
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with current knowledge. When survival curves for larger cohorts
become available, Bayesian methods can be used to update esti-
mates in Table 1 and reduce uncertainty of future predictions.
Discussion
Our model is, to our knowledge, the first to quantify the required
efficacy of LRAs for HIV-1 and set goals for therapy. For a wide
range of parameters, we find that therapies must reduce the LR
by at least 2 orders of magnitude to meaningfully increase time
to rebound after ART interruption (upward inflection in Figs. 2B
and 3 A, II; B, II; C, II), and that reductions of approximately 4
orders of magnitude are needed for half of patients to clear
the infection (Figs. 3 A, I; B, I; C, I; and 4). Standard deviations
in rebound times of many months are expected, owing to sub-
stantial variation in reactivation times after effective LRA
therapy brings the infection to an activation-limited regime.
Though the efficacy required for these beneficial outcomes likely
exceeds the reach of current drugs, our results permit some
optimism: We show for the first time, to our knowledge, that
reactivation of all cells in the reservoir is not necessary for ces-
sation of ART. This is because some cells in the LR will die
before reactivating or, following activation, will fail to produce
a chain of infections leading to rebound. On a more cautionary
note, the wide distribution in reactivation times necessitates
careful monitoring of patients, as rebound may occur even after
long periods of viral suppression.
Even without any reservoir reduction, variation in infection
parameters and chance activation together predict delays in re-
bound of at least 2 mo in a small minority of patients (Figs. 3 A,
III and 4), consistent with ART interruption trials such as
SPARTAC (40). More detailed (and possibly more speculative)
models including immune responses may be needed to explain
multiyear posttreatment control, such as seen in the VISCONTI
cohort (24).
Our analysis characterizing the required efficacy of LRA
therapy does not rely on the specific mechanism of action of
these drugs, only the amount by which they reduce the reservoir.
We have assumed that, after ART/LRA therapy ends, cell acti-
vation and death rates return to baseline. We have also assumed
that the reservoir is a homogeneous population with constant
activation and death rates. The presence of reservoir compart-
ments with different levels of LRA penetration does not alter
our results, as they are stated in terms of total reservoir re-
duction. If, however, these compartments vary in activation or
death rates (41), or if dynamics of activated cells depends on their
source compartment, then our model may need to be modified.
Moreover, if spatial population structure affects viral replication,
viral dynamics above the detection limit (from which we estimated
parameters r and A) may not correspond straightforwardly to the
infection/death rates in early infection, due to local limitations in
target cell density (42). Spatial restrictions on viral transmission
may be particularly important in densely packed lymphoid tissue
(43). Without a clear understanding of multiple compartments
constituting the LR, we have considered the simplest scenario
which may fit future LRA therapy outcomes.
Throughout this paper, we assume that combination ART is
sufficiently effective so that viral replication alone cannot sustain
the infection after all latent virus is cleared. Studies of treatment
intensification (44, 45), viral evolution during ART (46, 47), and
in vitro antiviral efficacy (48, 49) all support this assumption.
Moreover, HIV persistence is widely believed to result solely
from the long lifespan or proliferative ability of latently infected
cells (3, 50). If this assumption is violated, e.g., by the presence
of long-lived drug-protected compartments (43, 51, 52), then any
curative strategy predicated solely on latency reversal would
be futile.
Our model also highlights the importance of measuring spe-
cific parameters describing latency and infection dynamics. De-
spite the field’s focus on measuring LR size with increasing
accuracy (53), our results suggest that the rate at which latently
infected cells activate, and the fraction of these that are expected
to establish a rebounding infection, are more predictive of LRA
outcomes. Among all parameters that determine outcome, the
establishment probability is least understood, as it cannot be
measured from viral load dynamics above the limit of detection.
Simply because an integrated provirus is replication competent
and transcriptionally active does not mean that it will initiate
a growing infection: As with all population dynamics, chance
events dominate early stages of infection growth (34, 54). HIV-1
transcription is itself a stochastic process, governed by fluctuat-
ing concentrations of early gene products (55). Sensitive assays
of viral outgrowth may pave the way toward understanding the
importance of these chance events to early infection; for in-
stance, fluorescent imaging studies of adenovirus have shown
that a large majority of in vitro infections seeded by single pro-
ductively infected cells die out early, before rapid growth and
plaque formation can occur (54). Keeping other parameters
constant, assuming a worst-case (highest) value for the estab-
lishment probability raises the reservoir reductions required for
cure or a desired extended rebound time by 0.8 logs. Regardless
of the exact probability, the stochastic nature of HIV-1 activation
and infection dynamics implies that even similarly situated
patients may experience divergent responses to LRA.
The model can also advise aspects of trial design for LRAs.
Survival curves computed from [S8] can be used to predict the
probability that a patient is cured, given that they have been off
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LR half-life 44 months Fig. 3. Predicted LRA therapy outcomes, accounting for un-
certainty in patient parameter values. (A) Full uncertainty
analysis where all viral dynamics parameters are sampled for
each patient from the distributions provided in Table 1. (B) A
best-case scenario where the reservoir half-life is only 6 mo
(δ = 3.8 × 10−3 d−1). All patients have the same underlying
viral dynamic parameters, otherwise given by the point esti-
mates in Table 1. (C) A worst-case scenario where the reser-
voir does not decay because cell death is balanced by
homeostatic proliferation (δ = 0). (I) Probability that the LR is
cleared by LRA. Clearance occurs if all cells in the LR die before
a reactivating lineage leads to viral rebound. LRA log-efficacy
is the number of orders of magnitude by which the LR size is
reduced following LRA therapy, −log10(q). (II) Median viral
rebound times (logarithmic scale) among patients who do
not clear the infection. (III) Survival curves (Kaplan–Meier
plots) show the percentage of patients who have not yet
experienced viral rebound, plotted as a function of the time
(logarithmic scale) after treatment interruption. All simu-
lations included 104 to 105 patients.
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treatment without rebound for a known period. As frequent viral
load testing for years of postinterruption monitoring is not fea-
sible, it may be helpful to choose sampling time points based on
the expected distribution of rebound times. Trial design is
complicated by the fact that LRA treatment efficacy is unknown
if posttreatment LR size is below the detection limit. By con-
sidering prior knowledge about viral dynamic parameters and the
range of possible treatment efficacies, the model may estimate
outcomes even in the presence of uncertainty.
To date, laboratory and clinical studies of investigational
LRAs have generally found weak potential for reservoir re-
duction—up to 1 log-reduction in vitro and less in vivo (12, 26,
56). We predict that much higher efficacy will be required for
eradication, which may be achieved by multiple rounds of LRA
therapy, a combination of therapies, or development of therapies
to which a greater fraction of the LR is susceptible. Though we
have focused on LRA therapy, our findings also serve to in-
terpret infection eradication or delays in rebound caused by early
treatment (24, 25, 57) or stem cell transplantation (22, 23), both
of which also reduce the LR. In both of these cases, however,
additional immunological dynamics likely play a major role and
will need to be incorporated into future models. We believe that
these modeling efforts will provide a quantitative framework for
interpreting clinical trials of any reservoir-reduction strategy.
Materials and Methods
Basic Stochastic Model. The basic model of reservoir dynamics and rebound
tracks two cell types: productively infected activated CD4+ T cells and latently
infected resting CD4+ T cells. The model can be described formally as a two-
type branching process, in which four types of events can occur (Fig. 1):
Z→Y rate constant : a
Z→Ø rate constant : dz
Y→ cY rate constant : b×pλðcÞ
Y→Ø rate constant : d:
[2]
In this notation, Y and Z represent individual actively or latently infected
cells, respectively, Ø represents no cells, and the arrows represent one type
of cell becoming the other type. A latently infected cell can either activate
(at rate a) or die (at rate dz). An actively infected cell can either die (at rate
d) or produce a collection of virions (at rate b) that results in the infection of
c other cells, where c is a Poisson-distributed random variable with param-
eter λ, pλ(c) = (exp(−λ)λc)/(c!). After an infection event, the original cell dies.
Each event occurs independently within a large, constant target cell
population. As the model does not include limitations on viral growth, it
describes only the initial stages of viral rebound. Because clinical rebound
thresholds (plasma HIV RNA >50–200 copies per mL) are well below typical
set points (104 to 106 copies per mL), this model suffices to analyze re-
bound following LRA therapy and ART interruption. We do not explicitly
track free virus, but assume it to be proportional to the number of
infected cells. This assumption is valid because rates governing production
and clearance of free virus greatly exceed other rates, allowing a separa-
tion of time scales. As we are not interested in blips or other intraday viral
dynamics, this assumption does not influence our results. A method for
calculating the proportionality between free virus and infected cells is
provided in SI Materials and Methods.
The growth rate of the infection is r = b(λ − 1) − d. The total death rate of
infected cells is dy = b + d, and the basic reproductive ratio (mean offspring
number for a single infected cell) is R0 =bλ=ðb+dÞ. The establishment prob-
ability PEst is the solution to R0ð1− e−λPEst Þ− λPEst = 0. The total LR decay rate in
the absence of viral replication is δ = a + dz. If there are Z cells in the LR, then
the number of cells reactivating per day is A=Za.
Analysis of the model to determine the four key parameters (δ, A, r, PEst)
and rapidly compute survival curves is provided in SI Materials and Methods.
A script for computation of survival curves is also provided at www.
danielrosenbloom.com/reboundtimes.
Parameter Estimation. The half-life of latently infected cells has been esti-
mated to be approximately τ1/2 = 44 mo (3, 4). The resulting value of δ =
ln(2)/τ1/2 is centered at 5.2 × 10
−4 d−1, and we construct a distribution of
values based on ref. 3. This value represents the net rate of LR decay
during suppressive therapy, considering activation, death, homeostatic pro-
liferation, and (presumably rare) events where activated CD4+ T cells reenter
a memory state. The net infection growth rate r describes the rate of ex-
ponential increase in viral load once infection has been reseeded. The LR
reactivation rate A is the number of cells exiting the LR per day, before LRA
therapy. A and r were jointly estimated from the dynamics of viral load
during treatment interruption trials in which there was no additional res-
ervoir-reducing intervention (5, 58); in particular, infection growth imme-
diately following rebound is sensitive to r, whereas the time to rebound is
sensitive to A. Absent reservoir reduction, observed rebound dynamics are
insensitive to PEst, and so this parameter was instead estimated from pop-
ulation genetic models (59, 60) relating observed rates of selective sweeps
and emergence of drug resistance to variance in the viral offspring distri-
bution (SI Materials and Methods).
Simulation of the Model. We use the Gillespie algorithm to track the number
of latently and actively infected cells in a continuous time stochastic process.
The initial number of latent cells is Zð0Þ≈BinomialðNLR,qÞ, where NLR is
pretreatment LR size and q is efficacy of LRA treatment (fraction of cells
remaining). The initial number of actively infected cells Yð0Þ is then chosen
from a Poisson distribution with parameter aZð0Þ=dy (corresponding to the
immigration–death equilibrium of the branching process). The simulation
proceeds until the number of actively infected cells reaches the threshold for
clinical detection given by a viral load of 200 copies per mL (equivalent to
Y =3× 105 cells total) or until no active or latent cells remain. Because sto-
chastic effects are important only for small Y, we switch to faster de-
terministic numerical integration when Y reaches a level where extinction
probability is very low (<10−4). For each q value we perform 104 to 105
simulations.
Simulations are seeded with values of the key parameters (δ, A, r, PEst),
which may be either the point estimates or random numbers sampled from
the distributions in Table 1. We then back out values of model-specific
parameters consistent with the sampled key parameters. In general, we use
a pretherapy LR size of NLR = 10
6 cells to get a = A/NLR. We then have dz =
δ − a. As detailed in SI Materials and Methods, sampling PEst requires first
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Fig. 4. Efficacies required for successful LRA therapy. The target LRA log-
efficacy is the treatment level (in terms of log reduction in LR size) for which
at least 50% of patients still have suppressed viral load after a given treat-
ment interruption length (blue line). Shaded ranges show the results for the
middle 50% (dark gray) and 90% (light gray) of patients. Lifetime indicates
the LR is cleared. Annotations on the curve represent data points for case
studies describing large reservoir reductions and observing rebound times
after ART interruption. From left to right, they represent a case of early ART
initiation in an adult [the “Chun patient” (C.) (36)], two cases of hemato-
poietic stem cell transplant with wild-type donor cells [the two Boston
patients (Bo.1 and Bo.2) (23)], a case of early ART initiation in an infant [the
Mississippi baby (Mi.) (25), assuming, as recently reported, rebound after
27 mo], and a case of hematopoietic stem cell transplant with Δ32 CCR5 donor
cells [the Berlin patient (Be.) (22, 37)]. For the Chun patient, the annotations
represent the maximum likelihood estimate for LR reduction (diamond), as
well as 95% confidence intervals (vertical bar). For the Boston, Berlin, and
Mississippi patients, vertical arrows indicate that only a lower bound on
treatment efficacy is known (LR size was below the detection limit) and that
the true value may extend further in the direction shown. For the Berlin
patient, the horizontal arrow indicates that rebound time is at least 5 y
(rebound has not yet occurred).
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sampling the variance-to-mean ratio of the viral offspring distribution (ρ).
Then using r and ρ along with dy = d + b = 1 d
−1, we can obtain λ, b, d, and
PEst. Consistent with our generating function analysis, we find that the
specific values assumed for NLR and dy do not influence the results. For
simulating other models, any other parameter assumptions are listed in the
corresponding SI figure legends.
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